# A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

> **NCT06799741** · PHASE2 · COMPLETED · sponsor: **AbViro LLC** · enrollment: 85 (actual)

## Conditions studied

- DENV-3 Controlled Human Infection Model

## Interventions

- **DRUG:** AV-1 100 mg
- **DRUG:** AV-1 300 mg
- **DRUG:** AV-1 900 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06799741
- **Lead sponsor:** AbViro LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-07
- **Primary completion:** 2026-03-11
- **Final completion:** 2026-03-11
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06799741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06799741, "A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06799741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*